and Antifungal Activity of Buparvaquone Against

Overview

Journal Antimicrob Agents Chemother

Publisher American Society for Microbiology

Specialty Pharmacology

Date 2021 Jun 21

PMID 34152816

Citations 8

Authors

Luana Pereira Borba-Santos

Thayna Lopes Barreto

Taissa Vila

Kung Darh Chi

Fabiana Dos Santos Monti

Marconi Rodrigues de Farias

Daniela S Alviano

Celuta S Alviano

Debora O Futuro

Vitor Ferreira

Wanderley De Souza

Kelly Ishida

Sonia Rozental

Affiliations

Soon will be listed here.

Abstract

Sporotrichosis has become an important zoonosis in Brazil, and is the primary species transmitted by cats. Improvement of animal treatment will help control and limit the spread and geographic expansion of sporotrichosis. Accordingly, buparvaquone, an antiprotozoal hydroxynaphthoquinone agent marketed as Butalex, was evaluated and against feline-borne isolates of . Buparvaquone inhibited fungal growth at concentrations 4-fold lower than itraconazole (the first-choice antifungal used for sporotrichosis) and was 408 times more selective for than mammalian cells. Yeasts treated with a subinhibitory concentration of buparvaquone exhibited mitochondrial dysfunction, reactive oxygen species and neutral lipid accumulation, and impaired plasma membranes. Scanning electron microscopy images also revealed buparvaquone altered cell wall integrity and induced cell disruption. experiments in a Galleria mellonella model revealed that buparvaquone (single dose of 5 mg/kg of body weight) is more effective than itraconazole against infections with yeasts. Combined, our results indicate that buparvaquone has a great and antifungal activity against , revealing the potential application of this drug as an alternative treatment for feline sporotrichosis.

Citing Articles

Antifungal activity of indolicidin-derived peptide In-58 against and .

Li S, Tang Z, Liu Z, Lv S, Yao C, Wang S Front Med (Lausanne). 2024; 11:1458951.

PMID: 39328314 PMC: 11424419. DOI: 10.3389/fmed.2024.1458951.

Strategies of Pharmacological Repositioning for the Treatment of Medically Relevant Mycoses.

Gomez-Gaviria M, Contreras-Lopez L, Aguilera-Dominguez J, Mora-Montes H Infect Drug Resist. 2024; 17:2641-2658.

PMID: 38947372 PMC: 11214559. DOI: 10.2147/IDR.S466336.

A Theileria annulata parasite with a single mutation, methionine 128 to isoleucine (M128I), in cytochrome B is resistant to buparvaquone.

Tajeri S, Chattopadhyay D, Langsley G, Nijhof A PLoS One. 2024; 19(4):e0299002.

PMID: 38626086 PMC: 11020719. DOI: 10.1371/journal.pone.0299002.

Infection Modulates Antimicrobial Peptides and Stress Management Gene Expression in the Invertebrate Biomodel .

Reis N, de Jesus M, de Souza L, Martins Alcantara L, Rodrigues J, Brito S J Fungi (Basel). 2023; 9(11).

PMID: 37998858 PMC: 10672515. DOI: 10.3390/jof9111053.

: Epidemiology, Therapy, and Recent Developments.

Xavier M, Poester V, Trapaga M, Stevens D J Fungi (Basel). 2023; 9(9).

PMID: 37755029 PMC: 10532502. DOI: 10.3390/jof9090921.

References

Nyagwange J, Awino E, Tijhaar E, Svitek N, Pelle R, Nene V . Leveraging the Medicines for Malaria Venture malaria and pathogen boxes to discover chemical inhibitors of East Coast fever. Int J Parasitol Drugs Drug Resist. 2019; 9:80-86. PMC: 6376154. DOI: 10.1016/j.ijpddr.2019.01.002. View

Kamal Azam N, Selvarajah G, Santhanam J, Abdul Razak M, Jane Ginsapu S, James J . Molecular epidemiology of Sporothrix schenkii isolates in Malaysia. Med Mycol. 2019; 58(5):617-625. DOI: 10.1093/mmy/myz106. View

Mantyla A, Rautio J, Nevalainen T, Vepsalainen J, Juvonen R, Kendrick H . Synthesis and antileishmanial activity of novel buparvaquone oxime derivatives. Bioorg Med Chem. 2004; 12(13):3497-502. DOI: 10.1016/j.bmc.2004.04.032. View

Loh J, Adenwalla N, Wiles S, Proft T . Galleria mellonella larvae as an infection model for group A streptococcus. Virulence. 2013; 4(5):419-28. PMC: 3714134. DOI: 10.4161/viru.24930. View

Garnier T, Mantyla A, Jarvinen T, Lawrence J, Brown M, Croft S . In vivo studies on the antileishmanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother. 2007; 60(4):802-10. DOI: 10.1093/jac/dkm303. View

Waller S, Dalla Lana D, Quatrin P, Ferreira M, Fuentefria A, Mezzari A . Antifungal resistance on Sporothrix species: an overview. Braz J Microbiol. 2020; 52(1):73-80. PMC: 7966672. DOI: 10.1007/s42770-020-00307-z. View

Rossow J, Queiroz-Telles F, Caceres D, Beer K, Jackson B, Pereira J . A One Health Approach to Combatting : Narrative Review of an Emerging Zoonotic Fungal Pathogen in South America. J Fungi (Basel). 2020; 6(4). PMC: 7712324. DOI: 10.3390/jof6040247. View

Geltinger F, Schartel L, Wiederstein M, Tevini J, Aigner E, Felder T . Friend or Foe: Lipid Droplets as Organelles for Protein and Lipid Storage in Cellular Stress Response, Aging and Disease. Molecules. 2020; 25(21). PMC: 7663626. DOI: 10.3390/molecules25215053. View

Reimao J, Colombo F, Pereira-Chioccola V, Tempone A . Effectiveness of liposomal buparvaquone in an experimental hamster model of Leishmania (L.) infantum chagasi. Exp Parasitol. 2012; 130(3):195-9. DOI: 10.1016/j.exppara.2012.01.010. View

10.

da Costa-Silva T, Jimenez Galisteo Jr A, Lindoso J, Barbosa L, Tempone A . Nanoliposomal Buparvaquone Immunomodulates Leishmania infantum-Infected Macrophages and Is Highly Effective in a Murine Model. Antimicrob Agents Chemother. 2017; 61(4). PMC: 5365673. DOI: 10.1128/AAC.02297-16. View

11.

Jemel S, Guillot J, Kallel K, Botterel F, Dannaoui E . for the Evaluation of Antifungal Efficacy against Medically Important Fungi, a Narrative Review. Microorganisms. 2020; 8(3). PMC: 7142887. DOI: 10.3390/microorganisms8030390. View

12.

Futuro D, Ferreira P, Nicoletti C, Borba-Santos L, da Silva F, Rozental S . The Antifungal Activity of Naphthoquinones: An Integrative Review. An Acad Bras Cienc. 2018; 90(1 Suppl 2):1187-1214. DOI: 10.1590/0001-3765201820170815. View

13.

Gremiao I, Rocha E, Montenegro H, Carneiro A, Xavier M, de Farias M . Guideline for the management of feline sporotrichosis caused by Sporothrix brasiliensis and literature revision. Braz J Microbiol. 2020; 52(1):107-124. PMC: 7966609. DOI: 10.1007/s42770-020-00365-3. View

14.

Clavijo-Giraldo D, Matinez-Alvarez J, Lopes-Bezerra L, Ponce-Noyola P, Franco B, Almeida R . Analysis of Sporothrix schenckii sensu stricto and Sporothrix brasiliensis virulence in Galleria mellonella. J Microbiol Methods. 2016; 122:73-7. DOI: 10.1016/j.mimet.2016.01.014. View

15.

Murphy M . Mitochondrial dysfunction indirectly elevates ROS production by the endoplasmic reticulum. Cell Metab. 2013; 18(2):145-6. DOI: 10.1016/j.cmet.2013.07.006. View

16.

Borba-Santos L, Vila T, Rozental S . Identification of two potential inhibitors of Sporothrix brasiliensis and Sporothrix schenckii in the Pathogen Box collection. PLoS One. 2020; 15(10):e0240658. PMC: 7556523. DOI: 10.1371/journal.pone.0240658. View

17.

Muller J, Aguado-Martinez A, Manser V, Wong H, Haynes R, Hemphill A . Repurposing of antiparasitic drugs: the hydroxy-naphthoquinone buparvaquone inhibits vertical transmission in the pregnant neosporosis mouse model. Vet Res. 2016; 47:32. PMC: 4756515. DOI: 10.1186/s13567-016-0317-1. View

18.

Katragkou A, Roilides E, Walsh T . Can repurposing of existing drugs provide more effective therapies for invasive fungal infections?. Expert Opin Pharmacother. 2016; 17(9):1179-82. DOI: 10.1080/14656566.2016.1186647. View

19.

Nakasu C, Waller S, Ripoll M, Ferreira M, Conceicao F, Dos Reis Gomes A . Feline sporotrichosis: a case series of itraconazole-resistant Sporothrix brasiliensis infection. Braz J Microbiol. 2020; 52(1):163-171. PMC: 7966689. DOI: 10.1007/s42770-020-00290-5. View

20.

Pfaller M, Sheehan D, Rex J . Determination of fungicidal activities against yeasts and molds: lessons learned from bactericidal testing and the need for standardization. Clin Microbiol Rev. 2004; 17(2):268-80. PMC: 387411. DOI: 10.1128/CMR.17.2.268-280.2004. View